Efficacy and safety of berberine on metabolic abnormalities in women with polycystic ovary syndrome by systematic review and Meta-analysis
Liu Zhen, Yin Dongmei, Zhan Sien, Ruan Xiangyan
2021, 42(4):
588-595.
doi:10.3969/j.issn.1006-7795.2021.04.013
Asbtract
(
134 )
PDF (1288KB)
(
38
)
References |
Related Articles |
Metrics
Objectives To evaluate the efficacy and safety of berberine on polycystic ovary syndrome(PCOS)patients with metabolic abnormalities. Methods CNKI, Wanfang Data, VIP, PubMed, ELSEVIER and Cochrane Library were searched for randomized controlled trials in human beings, till June 2020. Relevant indicators were collected and the data were analyzed by using RevMan 5.0 software. Results A total of 11 studies, 2 English articles and 9 Chinese articles were included. Our study showed that berberine (BBR) improved better than metformin (MET) on waist-hip ratio(WHR)(MD=-0.03,95%CI:-0.04--0.01), fasting insulin(FIN)(MD=-1.91,95%CI:-3.56--0.25),total cholesterol(TC)((MD=-0.37,95%CI:-0.68--0.06),high density lipoprotein cholesterol(HDL-C)( MD=-0.15,95%CI:-0.31-0.00) and low density lipoprotein cholesterol (LDL-C)( MD=-0.34,95%CI:-0.56--0.13), but not on body mass index(BMI)(MD=-0.09,95%CI:-0.97-0.80),fasting plasma glucose (FPG)(MD=0.09,95%CI:-0.03-0.21),homeostasis model assessment of insulin resistance(HOMA-IR)(MD=-0.25,95%CI:-0.58-0.07),total testosterone (TT) (MD=-0.13,95%CI:-0.26-0.01), and worse on triglyceride (TG) (MD=0.11,95%CI:0.02-0.20). Compared with COC alone, BBR combined with COC improved better on WHR(MD=-0.03,95%CI:-0.04--0.03), FPG(MD=-0.34,95%CI:-0.57--0.11),FIN(MD=-3.39,95%CI:-5.16--1.62),HOMA-IR(MD=-1.12,95%CI:-1.73--0.51),TC(MD=-0.50,95%CI:-0.58--0.42),TG(MD=-0.23,95%CI:-0.36--0.11),HDL-C(MD=0.11,95%CI:0.09-0.14),LDL-C(MD=-0.43,95%CI:-0.53--0.33)和TT(MD=-0.14,95%CI:-0.25--0.03),but not on BMI(MD=-0.41,95%CI:-1.07-0.24). There was no statistically significant difference on the incidence of adverse reactions between BBR and MET (RR=0.58,95%CI:0.32-1.07),and BBR combined with COC and COC alone(RR=1.85,95%CI:0.77-4.46). Conclusion BBR could improve clinical outcomes on metabolic abnormalities in women with PCOS. However, the effectiveness and safety need to be further verified by high-quality, large-sample, multi-center RCTs.